Erleada drug combination extends progression-free survival in prostate cancer trial
In the Phase III ACIS study, prostate cancer patients treated…
In the Phase III ACIS study, prostate cancer patients treated with a combination of Erleada® and Zytiga® plus prednisone were less likely to die than participants receiving Zytiga and prednisone.